Compare ROK & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROK | INSM |
|---|---|---|
| Founded | 1903 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 41.2B |
| IPO Year | 1987 | 2000 |
| Metric | ROK | INSM |
|---|---|---|
| Price | $423.81 | $157.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | ★ $415.77 | $190.64 |
| AVG Volume (30 Days) | 659.0K | ★ 2.6M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.67 | N/A |
| Revenue | ★ $8,342,000,000.00 | $447,022,000.00 |
| Revenue This Year | $7.12 | $53.83 |
| Revenue Next Year | $5.82 | $138.44 |
| P/E Ratio | $54.09 | ★ N/A |
| Revenue Growth | 0.94 | ★ 30.34 |
| 52 Week Low | $215.00 | $60.40 |
| 52 Week High | $429.58 | $212.75 |
| Indicator | ROK | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.85 | 40.62 |
| Support Level | $413.71 | $153.09 |
| Resistance Level | $429.58 | $165.47 |
| Average True Range (ATR) | 8.14 | 7.60 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 83.34 | 18.19 |
With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.